Cystic Fibrosis (CF) Clinical Trial
Official title:
Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Urine After a Short Pause of Therapy
Verified date | February 2023 |
Source | University of Aarhus |
Contact | Amalie Q. Rousing, BM |
arousing[@]biomed.au.dk | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In cystic fibrosis (CF) renal base excretion is impaired, due to mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, since CFTR function is crucial in regulation of the kidney's HCO3- excretion. The investigators suggest that challenged urine HCO3- excretion is a biomarker of CFTR function, which can be used to evaluate the extent of CFTR dysfunction and the possible correcting effects of CFTR modulating therapy. This study aims to evaluate changes in challenged urine HCO3- excretion in CF patients, who are currently in treatment with the triple CFTR modulator combination therapy, Elexacaftor/tezacaftor/ivacaftor (ETI), before, during, and after a short treatment pause.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult (age >17 years) CF patients. - Normal kidney function estimated by eGFR>90. - Adults capable of understanding and voluntarily consenting. Exclusion Criteria: - Critical acute illness. - Severe lung disease (ppFEV1<40%). - Adults not capable of understanding and voluntarily consenting. |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Infectious Diseases, Aarhus University Hospital | Aarhus C | Midtjylland |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Berg P, Sorensen MV, Rousing AQ, Vebert Olesen H, Jensen-Fangel S, Jeppesen M, Leipziger J. Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis. Ann Intern Med. 2022 Nov;175(11):1543-1551. doi: 10.7326/M22-1741. Epub 2022 Nov 1. — View Citation
Berg P, Svendsen SL, Sorensen MV, Larsen CK, Andersen JF, Jensen-Fangel S, Jeppesen M, Schreiber R, Cabrita I, Kunzelmann K, Leipziger J. Impaired Renal HCO3- Excretion in Cystic Fibrosis. J Am Soc Nephrol. 2020 Aug;31(8):1711-1727. doi: 10.1681/ASN.2020010053. Epub 2020 Jul 23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in cumulative urine bicarbonate excretion before, during, and after ETI pause. | Challenged urine HCO3- test: Quantification of urine bicarbonate excretion after an acute oral NaHCO3 challenge before, under, and after ETI pause. | At baseline, after 12/36/60 hours of therapy pause and after therapy is resumed. | |
Primary | Link between changes in ETI plasma concentration and changes in urine bicarbonate excretion. | Venous blood sampling: ETI plasma concentration measurement. Challenged urine HCO3- test: Quantification of urine bicarbonate excretion | At baseline, after 12/36/60 hours of therapy pause and after therapy is resumed. | |
Secondary | Link between plasma acid-base status and urine acid-base excretion. | Venous blood sampling: Venous acid-base measurements. | At baseline, after 12/36/60 hours of therapy pause and after therapy is resumed. | |
Secondary | Changes in plasma concentration of ETI during the trial. | Venous blood sampling: ETI plasma concentration measurement. | At baseline, after 12/36/60 hours of therapy pause and after therapy is resumed. | |
Secondary | Changes in acid-base and fluid status during the trial. | Venous blood sampling: Venous acid-base and fluid measurements. | At baseline, after 12/36/60 hours of therapy pause and after therapy is resumed. | |
Secondary | Changes in electrolytes during the trial. | Venous blood sampling: Venous electrolyte measurements. Challenged HCO3- urine test: Urine electrolyte measurements. | At baseline, after 12/36/60 hours of therapy pause and after therapy is resumed. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04853368 -
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
|
Phase 2 | |
Terminated |
NCT03234387 -
A CFit Study - Baseline
|
||
Completed |
NCT03445793 -
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
|
||
Completed |
NCT02778750 -
Evaluation Of The Pan-microbiome and Host Immune Response in CF
|
||
Completed |
NCT00677365 -
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
|
Phase 2 | |
Terminated |
NCT03597347 -
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
|
Phase 2 | |
Completed |
NCT04375878 -
OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
|
Phase 2 | |
Withdrawn |
NCT01951833 -
Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis
|
N/A | |
Completed |
NCT03746483 -
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 2 | |
Completed |
NCT02163681 -
MRI for Non-Invasive Imaging in Neonates and Children
|
N/A | |
Completed |
NCT02036879 -
Gender Disparity and Hormones in Cystic Fibrosis
|
Early Phase 1 | |
Completed |
NCT02605590 -
Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT01851642 -
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
|